Marksans Pharma Limited (BOM:524404)
India
· Delayed Price · Currency is INR 249.95
-2.00 (-0.79%)
At close: May 28, 2025
Marksans Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 26,228 | 21,774 | 18,521 | 14,908 | 13,762 | Upgrade
|
| Revenue | 26,228 | 21,774 | 18,521 | 14,908 | 13,762 | Upgrade
|
| Revenue Growth (YoY) | 20.46% | 17.56% | 24.23% | 8.33% | 21.32% | Upgrade
|
| Cost of Revenue | 11,437 | 10,693 | 9,401 | 7,295 | 6,056 | Upgrade
|
| Gross Profit | 14,791 | 11,081 | 9,120 | 7,613 | 7,706 | Upgrade
|
| Selling, General & Admin | 3,503 | 3,059 | 2,523 | 2,250 | 2,096 | Upgrade
|
| Other Operating Expenses | 6,002 | 3,436 | 3,202 | 2,774 | 2,204 | Upgrade
|
| Operating Expenses | 10,339 | 7,238 | 6,243 | 5,472 | 4,614 | Upgrade
|
| Operating Income | 4,453 | 3,843 | 2,877 | 2,141 | 3,092 | Upgrade
|
| Interest Expense | -116.6 | -112.03 | -60.96 | -57.4 | -38.17 | Upgrade
|
| Interest & Investment Income | - | 337.87 | 120.37 | 59.73 | 11.59 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 82.4 | 397.77 | 205.79 | -9.67 | Upgrade
|
| Other Non Operating Income (Expenses) | 703.76 | 82.1 | 44.67 | 124.79 | 13.29 | Upgrade
|
| EBT Excluding Unusual Items | 5,040 | 4,233 | 3,379 | 2,474 | 3,069 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -47.9 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.52 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.94 | -2.64 | - | 0.3 | Upgrade
|
| Pretax Income | 5,040 | 4,235 | 3,377 | 2,475 | 3,022 | Upgrade
|
| Income Tax Expense | 1,213 | 1,086 | 723.32 | 606.97 | 636.26 | Upgrade
|
| Earnings From Continuing Operations | 3,826 | 3,149 | 2,653 | 1,868 | 2,385 | Upgrade
|
| Minority Interest in Earnings | -20.44 | -11.95 | 9.87 | - | - | Upgrade
|
| Net Income | 3,806 | 3,137 | 2,663 | 1,868 | 2,385 | Upgrade
|
| Net Income to Common | 3,806 | 3,137 | 2,663 | 1,868 | 2,385 | Upgrade
|
| Net Income Growth | 21.32% | 17.80% | 42.55% | -21.68% | 97.54% | Upgrade
|
| Shares Outstanding (Basic) | 453 | 453 | 415 | 409 | 409 | Upgrade
|
| Shares Outstanding (Diluted) | 453 | 453 | 415 | 409 | 409 | Upgrade
|
| Shares Change (YoY) | -0.02% | 9.09% | 1.49% | - | -0.00% | Upgrade
|
| EPS (Basic) | 8.40 | 6.92 | 6.41 | 4.56 | 5.83 | Upgrade
|
| EPS (Diluted) | 8.40 | 6.92 | 6.41 | 4.56 | 5.83 | Upgrade
|
| EPS Growth | 21.39% | 7.96% | 40.44% | -21.68% | 97.54% | Upgrade
|
| Free Cash Flow | 337.45 | 215.69 | 1,838 | 529.27 | 1,322 | Upgrade
|
| Free Cash Flow Per Share | 0.74 | 0.48 | 4.42 | 1.29 | 3.23 | Upgrade
|
| Dividend Per Share | 0.800 | 0.600 | 0.500 | 0.250 | 0.250 | Upgrade
|
| Dividend Growth | 33.33% | 20.00% | 100.00% | - | 150.00% | Upgrade
|
| Gross Margin | 56.39% | 50.89% | 49.24% | 51.07% | 56.00% | Upgrade
|
| Operating Margin | 16.98% | 17.65% | 15.53% | 14.36% | 22.47% | Upgrade
|
| Profit Margin | 14.51% | 14.41% | 14.38% | 12.53% | 17.33% | Upgrade
|
| Free Cash Flow Margin | 1.29% | 0.99% | 9.92% | 3.55% | 9.60% | Upgrade
|
| EBITDA | 5,286 | 4,337 | 3,203 | 2,405 | 3,351 | Upgrade
|
| EBITDA Margin | 20.16% | 19.92% | 17.30% | 16.13% | 24.35% | Upgrade
|
| D&A For EBITDA | 833.86 | 494.18 | 326.09 | 263.46 | 258.82 | Upgrade
|
| EBIT | 4,453 | 3,843 | 2,877 | 2,141 | 3,092 | Upgrade
|
| EBIT Margin | 16.98% | 17.65% | 15.53% | 14.36% | 22.47% | Upgrade
|
| Effective Tax Rate | 24.08% | 25.65% | 21.42% | 24.52% | 21.06% | Upgrade
|
| Revenue as Reported | 26,932 | 22,278 | 19,115 | 15,327 | 13,829 | Upgrade
|
Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.